Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway

Liao,Z. J.; Guo,Y.  H.; Zhao,Z.; Yao,J. T.; Xu,R.; Nan,K. J.

doi:10.3892/ijo.2014.2464

Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway

Authors:
- Z. J. Liao
- Y. H. Guo
- Z. Zhao
- J. T. Yao
- R. Xu
- K. J. Nan
View Affiliations

Affiliations: Department of Medical Oncology, Shaanxi Province Tumor Hospital, Xi'an, Shaanxi 710061, P.R. China , Department of Medical Oncology, The First Affiliated Hospital of The School of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: May 26, 2014 https://doi.org/10.3892/ijo.2014.2464
Pages: 651-658

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recurrence and metastasis are responsible for the death of non-small cell lung cancer (NSCLC) patients. Circulating tumor cells (CTCs) in the metastatic pathway have proven to be essential. This pilot study evaluated the sensitivity of gemcitabine in micrometastasis and CTCs from NSCLC patients. EpCAM-positive CTCs were detected in forty patients with NSCLC at treatment initiation and disease evaluation time-points. EpCAM-positive CTCs were defined as EpCAM-positive and CD45-negative. Total RNA was isolated from EpCAM-enriched CTCs and cytokeratin levels were detected by PCR. The HGF/cMET pathway was evaluated in CTCs from patients with different treatments and in A549 cells. The EMT-related markers were analyzed by IHC. We further explored the predictive value of baseline CTCs in patients that were receiving different treatments. The median number of CTCs in NSCLC patients was 65 CTCs/ml more than in the healthy 23?fold (median, 5.2 CTCs/ml). The mean change in cell count was significantly different for patients with gemcitabine compared to patients with non-gemcitabine treatments (-86.28 vs. -15.23/ml; P<0.05). A significant decrease was noted in the expression of cytokeratin in the CTCs of the two groups (P<0.05). The HGF/cMET pathway was inactivated in CTCs and A549 cells treated with gemcitabine, and the cell migration and invasion abilities were inhibited by gemcitabine via the HGF/cMET pathway. Furthermore, the decreased cell migration and invasion abilities may also be involved in the inhibition of the epithelial-mesenchymal transition (EMT) by gemcitabine. At a median follow-up of 36 months, the CTC count was confirmed to be a robust prognostic marker in the NSCLC population (CTCs >151, median: 15.0 months and CTCs <151, median: 32.0 months). Additionally, the survival rate in the gemcitabine group (24 months) was better than in non-gemcitabine group (21 months), suggesting a therapeutic benefit for NSCLC patient survival with the common therapy plus gemcitabine. Gemcitabine treatment decreased EpCAM-positive CTCs in NSCLC patients and inhibited EMT by the HGF/cMET pathway.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ni X, Zhuo M, Su Z, et al: Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA. 110:21083–21088. 2013. View Article : Google Scholar
3	Plaks V, Koopman CD and Werb Z: Cancer. Circulating tumor cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
4	Li P, Stratton ZS, Dao M, Ritz J and Huang TJ: Probing circulating tumor cells in microfluidics. Lab Chip. 13:602–609. 2013. View Article : Google Scholar
5	Young R, Pailler E, Billiot F, et al: Circulating tumor cells in lung cancer. Acta Cytol. 56:655–660. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Qian J, Feng JG, et al: Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases. Cell Oncol (Dordr). 36:43–53. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hou HW, Warkiani ME, Khoo BL, et al: Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 3:12592013.PubMed/NCBI
8	Huang SB, Wu MH, Lin YH, et al: High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip. 13:1371–1383. 2013. View Article : Google Scholar : PubMed/NCBI
9	Diamond E, Lee GY, Akhtar NH, et al: Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol. 2:1312012. View Article : Google Scholar : PubMed/NCBI
10	Dong Y, Skelley AM, Merdek KD, et al: Microfluidics and circulating tumor cells. J Mol Diagn. 15:149–157. 2013. View Article : Google Scholar : PubMed/NCBI
11	Green TL, Cruse JM and Lewis RE: Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol. 95:174–179. 2013. View Article : Google Scholar : PubMed/NCBI
12	Lin HK, Zheng S, Williams AJ, et al: Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 16:5011–5018. 2010. View Article : Google Scholar : PubMed/NCBI
13	Alunni-Fabbroni M and Sandri MT: Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 50:289–297. 2010. View Article : Google Scholar : PubMed/NCBI
14	Ross JS and Slodkowska EA: Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol. 132:237–245. 2009. View Article : Google Scholar : PubMed/NCBI
15	Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D and Jirillo A: Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology. 76:375–386. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wen CY, Wu LL, Zhang ZL, et al: Quick-response magnetic nanospheres for rapid, efficient capture and sensitive detection of circulating tumor cells. ACS Nano. 8:941–949. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chen Q, Ge F, Cui W, et al: Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta. 419:57–61. 2013. View Article : Google Scholar
18	Pantel K and Alix-Panabieres C: Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 16:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
19	Sieuwerts AM, Kraan J, Bolt J, et al: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 101:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
20	Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003.
21	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
22	Hugo H, Ackland ML, Blick T, et al: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chaffer CL, Thompson EW and Williams ED: Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 185:7–19. 2007. View Article : Google Scholar : PubMed/NCBI
24	Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
25	Zavadil J: New TGF-beta and Ras crosstalk in EMT. Cell Cycle. 8:1842009. View Article : Google Scholar : PubMed/NCBI
26	Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
27	Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
28	Akhurst RJ, Fitzpatrick DR, Fowlis DJ, Gatherer D, Millan FA and Slager H: The role of TGF-beta s in mammalian development and neoplasia. Mol Reprod Dev. 32:127–135. 1992. View Article : Google Scholar : PubMed/NCBI
29	Zhou HY, Pon YL and Wong AS: HGF/MET signaling in ovarian cancer. Curr Mol Med. 8:469–480. 2008. View Article : Google Scholar : PubMed/NCBI
30	Gesto DS, Cerqueira NM, Fernandes PA and Ramos MJ: Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem. 19:1076–1087. 2012. View Article : Google Scholar : PubMed/NCBI
31	Muggia F, Diaz I and Peters GJ: Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. Expert Opin Investig Drugs. 21:403–408. 2012. View Article : Google Scholar : PubMed/NCBI
32	Cok G, Goksel T, Soyer S and Aysan T: Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer. Tuberk Toraks. 56:74–80. 2008.PubMed/NCBI
33	Noble S and Goa KL: Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 54:447–472. 1997.PubMed/NCBI
34	Galsky MD, Hahn NM, Powles T, et al: Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 11:175–181. 2013. View Article : Google Scholar : PubMed/NCBI
35	Martin M, Ruiz A, Munoz M, et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 8:219–225. 2007. View Article : Google Scholar
36	Reaume MN, Leighl NB, Mittmann N, et al: Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer. 82:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
37	Gridelli C, Gallo C, Shepherd FA, et al: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 21:3025–3034. 2003.
38	Perlikos F, Harrington KJ and Syrigos KN: Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
39	Stott SL, Lee RJ, Nagrath S, et al: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2:25ra232010.PubMed/NCBI
40	Wallwiener M, Hartkopf AD, Baccelli I, et al: The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 137:503–510. 2013. View Article : Google Scholar : PubMed/NCBI
41	Ma J, Lin JY, Alloo A, et al: Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun. 402:711–717. 2010. View Article : Google Scholar : PubMed/NCBI